 Filter
|
|
|
Rhodotorula
|
|
|
|
|
|
|
GSE99872
|
Therapeutic antibodies to ganglioside GD2 evolved from highly selective germline antibodies I
|
|
|
6
|
|
|
Jeff Gildersleeve
|
Aug 25, 2017
|
|
GSE99873
|
Therapeutic antibodies to ganglioside GD2 evolved from highly selective germline antibodies II
|
|
|
14
|
|
|
Jeff Gildersleeve
|
Aug 25, 2017
|
|
GSE99874
|
Therapeutic antibodies to ganglioside GD2 evolved from highly selective germline antibodies III
|
|
|
7
|
|
|
Jeff Gildersleeve
|
Aug 25, 2017
|
|
GSE100307
|
Therapeutic antibodies to ganglioside GD2 evolved from highly selective germline antibodies IV
|
|
|
7
|
|
|
Jeff Gildersleeve
|
Aug 25, 2017
|
|
GSE100308
|
Therapeutic antibodies to ganglioside GD2 evolved from highly selective germline antibodies V
|
|
|
7
|
|
|
Jeff Gildersleeve
|
Aug 25, 2017
|
|
GSE100309
|
Therapeutic antibodies to ganglioside GD2 evolved from highly selective germline antibodies VI
|
|
|
7
|
|
|
Jeff Gildersleeve
|
Aug 25, 2017
|
|
GSE100310
|
Therapeutic antibodies to ganglioside GD2 evolved from highly selective germline antibodies VII
|
|
|
7
|
|
|
Jeff Gildersleeve
|
Aug 25, 2017
|
|
GSE100438
|
Therapeutic antibodies to ganglioside GD2 evolved from highly selective germline antibodies
|
|
|
55
|
|
|
Jeff Gildersleeve
|
Aug 25, 2017
|
|
GSE68403
|
Development of a glycan microarray based method for ABO blood typing
|
|
|
220
|
|
|
Jeff Gildersleeve
|
Apr 28, 2016
|
|
GSE68405
|
A Simple, Inexpensive Strategy for Predicting Potential Beneficial Clinical Responses on Prostate Cancer Vaccine Therapy
|
|
|
331
|
|
|
Jeff Gildersleeve
|
Apr 28, 2016
|
|
GSE50230
|
Post-vaccination serum anti-glycan IgG antibodies of 28 subjects in a clinical trial of PROSTVAC-VF, a therapeutic cancer vaccine. (Dilution = 1:50)
|
|
|
28
|
|
|
Christopher Campbell
|
Aug 26, 2015
|
|
GSE50231
|
Post-vaccination serum anti-glycan IgM antibodies of 28 subjects in a clinical trial of PROSTVAC-VF, a therapeutic cancer vaccine. (Dilution = 1:50)
|
|
|
28
|
|
|
Christopher Campbell
|
Aug 26, 2015
|
|
GSE50232
|
Post-vaccination serum anti-glycan total Ig antibodies of 28 subjects in a clinical trial of PROSTVAC-VF, a therapeutic cancer vaccine. (Dilution = 1:50)
|
|
|
28
|
|
|
Christopher Campbell
|
Aug 26, 2015
|
|
GSE50233
|
Post-vaccination serum anti-glycan total Ig antibodies of 28 subjects in a clinical trial of PROSTVAC-VF, a therapeutic cancer vaccine. (Dilution = 1:200)
|
|
|
28
|
|
|
Christopher Campbell
|
Aug 26, 2015
|
|
GSE50235
|
Post-vaccination serum anti-glycan IgG antibodies of 113 subjects in a clinical trial of PROSTVAC-VF, a therapeutic cancer vaccine. (Dilution = 1:50)
|
|
|
113
|
|
|
Christopher Campbell
|
Aug 26, 2015
|
|
GSE50236
|
Baseline serum anti-glycan total Ig antibodies of 113 subjects in a clinical trial of PROSTVAC-VF, a therapeutic cancer vaccine. (Dilution = 1:50)
|
|
|
113
|
|
|
Christopher Campbell
|
Aug 26, 2015
|
|
GSE50237
|
Baseline serum anti-glycan IgM antibodies of 113 subjects in a clinical trial of PROSTVAC-VF, a therapeutic cancer vaccine. (Dilution = 1:50)
|
|
|
113
|
|
|
Christopher Campbell
|
Aug 26, 2015
|
|
GSE50239
|
Post-vaccination serum anti-glycan total Ig antibodies of 113 subjects in a clinical trial of PROSTVAC-VF, a therapeutic cancer vaccine. (Dilution = 1:200)
|
|
|
113
|
|
|
Christopher Campbell
|
Aug 26, 2015
|
|
GSE50410
|
Anti-glycan humoral responses after vaccination with PROSTVAC-VF
|
|
|
564
|
|
|
Christopher Campbell
|
Aug 26, 2015
|
|
GSE42019
|
Baseline serum anti-glycan antibodies of 28 subjects in a clinical trial of PROSTVAC-VF, a therapeutic cancer vaccine [Training IgG 1:50]
|
|
|
28
|
|
|
Christopher Campbell
|
Apr 01, 2013
|
